TY - JOUR
T1 - The reintroduction of radiotherapy into the integrated management of kidney cancer
AU - Dohopolski, Michael
AU - Hannan, Raquibul
AU - Wardak, Zabi
AU - Hammers, Hans
AU - Garant, Aurelie
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - The incidence of renal cell carcinoma (RCC) has been increasing, with a moderate subgroup of individuals who later develop metastatic disease. Historically, metastatic RCC has been managed with systemic therapy because RCC was believed to be radioresistant. Local therapies, such as stereotactic body radiation therapy, also known as stereotactic ablative radiotherapy, which utilize focused high-dose-rate radiation delivered over a limited number of treatments, have been successful in controlling local disease and, in some cases, extending survival in patients with intracranial and extracranial metastatic RCC. Stereotactic ablative radiotherapy is highly effective in treating intact disease when patients are not surgical candidates. Stereotactic ablative radiotherapy is well tolerated when used in conjunction with systemic therapy such as tyrosine kinase inhibitors and immune checkpoint inhibitors. These successes have prompted investigators to evaluate the efficacy of stereotactic body radiation therapy in novel settings such as neoadjuvant treatment of advanced RCC with tumor thrombus and oligometastatic/oligoprogressive disease states.
AB - The incidence of renal cell carcinoma (RCC) has been increasing, with a moderate subgroup of individuals who later develop metastatic disease. Historically, metastatic RCC has been managed with systemic therapy because RCC was believed to be radioresistant. Local therapies, such as stereotactic body radiation therapy, also known as stereotactic ablative radiotherapy, which utilize focused high-dose-rate radiation delivered over a limited number of treatments, have been successful in controlling local disease and, in some cases, extending survival in patients with intracranial and extracranial metastatic RCC. Stereotactic ablative radiotherapy is highly effective in treating intact disease when patients are not surgical candidates. Stereotactic ablative radiotherapy is well tolerated when used in conjunction with systemic therapy such as tyrosine kinase inhibitors and immune checkpoint inhibitors. These successes have prompted investigators to evaluate the efficacy of stereotactic body radiation therapy in novel settings such as neoadjuvant treatment of advanced RCC with tumor thrombus and oligometastatic/oligoprogressive disease states.
KW - Checkpoint inhibitors
KW - intact kidney
KW - metastatic renal cell carcinoma
KW - renal cell carcinoma
KW - stereotactic ablative radiotherapy
KW - stereotactic body radiation therapy
KW - tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85091323673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091323673&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000475
DO - 10.1097/PPO.0000000000000475
M3 - Review article
C2 - 32947313
AN - SCOPUS:85091323673
SN - 1528-9117
VL - 26
SP - 448
EP - 459
JO - Cancer Journal
JF - Cancer Journal
IS - 5
ER -